Primers and Probes​

Custom oligonucleotides for detection of SARS-CoV-2

Syngene offers SARS-CoV-2 in-vitro and in-vivo research, in partnership with Foundation for Neglected Disease Research (FNDR). This non-exclusive partnership, aims to provide a range of non-BSL3 and BSL3 in vitro and in vivo capabilities to facilitate a wide variety of studies on SARS-CoV-2, and prepare us for the next wave of the corona virus pandemic.

Our joint offerings include:

  • In vitro immune profiling, mechanism of action studies (non-BSL3)
  • In vitro immunological assays (non-BSL3 cell-based assays and cytotoxicity assays)
  • In vitro cell-based assays for screening of novel compounds and libraries for antiviral activity, including pre-and post-entry viral inhibition studies, antiviral synergy studies, and neutralization assays for antibodies and vaccines against wild type SARS-CoV-2 strain
  • In vivo efficacy assay in Golden Syrian hamster with wild type SARS-CoV-2 infection model for antiviral inhibition, vaccines, neutralizing antibodies, and biologicals, for understanding biology, pathology, immunology parameters in an infection.

Therapeutic oligonucleotides for COVID-19 and other diseases

Oligonucleotide therapeutics is one of the most promising fields in modern medicine to treat several diseases which are genetic or non-genetic in nature by modulating gene expression.

Oligos face immense challenges for their use as therapeutics and these challenges must be resolved before proceeding with regulatory approvals. Since a highly complex nature of oligo drugs mandates novel and sophisticated process methods, Syngene has a complete dedicated facility for oligos which satisfy the cGMP requirements.

  • Oligonucleotides up to 60 nucleotides in length
    • Natural as well as modified
    • DNA as well as RNA
    • Single stranded as well as double stranded
    • Wide variety of modification and conjugation
  •  Quick turnaround times
  •  Non-GMP and cGMP grade
  •  100 mg to 135 g per batches